SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing significant downward pressure driven by market apprehension surrounding Donald Trump's extended and often incoherent public address, where his discussion of tariffs and Greenland policy raises concerns about global trade stability. Community sentiment is deeply divided, with many expressing alarm over potential economic repercussions while a subset anticipates a swift "buy the dip" recovery from the current volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant technology, widely seen by the community as a validation of its core platform. This development has fueled expectations of further partnerships and a potential short squeeze, with many closely watching how management addresses continued activist investor pressure for enhanced shareholder value.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in attention following a pivotal FDA meeting for its ANKTIVA bladder cancer treatment, where regulators reportedly indicated no requirement for new clinical trials and requested additional data for submission within 30 days. This news has ignited strong community discussion, with investors buzzing about a potential short squeeze and highlighting ANKTIVA's broad therapeutic promise across various cancer indications. The stock's robust performance amid a challenging market is drawing significant interest, as many anticipate further positive developments and substantial long-term growth for this biotech company.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

ProShares Ultra VIX Short-Term Futures ETF ($UVXY) is actively trending as traders weigh potential market volatility driven by discussions surrounding recent geopolitical developments, including international tariffs, and the anticipated Bank of Japan rate hike. The community is sharply divided, with many actively debating short positions on $UVXY due to its inherent decay, while others anticipate a volatility spike, expressing frustration over its subdued movement despite broader market fluctuations.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending following news of its strategic acquisition of a luxury wine authentication and trading business, diversifying its market beyond caviar. This has ignited significant discussion among traders, with many anticipating further price movement and highlighting strong volume, while others express concerns about a recent public offering and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT...

Promising Medical Stocks To Follow Today - January 20th

Rapt Therapeutics, Johnson & Johnson, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded...

Top Pharmaceutical Stocks To Follow Now - January 20th

Rapt Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Corvus Pharmaceuticals, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...

Rapt Therapeutics' (RAPT) "Hold" Rating Reaffirmed at TD Cowen

TD Cowen reiterated a "hold" rating on shares of Rapt Therapeutics in a report on Tuesday...

HC Wainwright Reaffirms "Neutral" Rating for Rapt Therapeutics (NASDAQ:RAPT)

HC Wainwright restated a "neutral" rating and set a $58.00 price objective on shares of Rapt Therapeutics in a report on Tuesday...

Rapt Therapeutics (NASDAQ:RAPT) Reaches New 1-Year High - Still a Buy?

Rapt Therapeutics (NASDAQ:RAPT) Hits New 52-Week High - Still a Buy...

Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether RAPT...

RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT shareholders. Halper Sadeh...

<ul class="summary-bullets"><li>GSK signed an agreement to acquire RAPT Therapeutics for around $2.2 billion.</li><li>The deal centers on an experimental allergy drug that could reshape treatment frequency and expand patient access.</li><li>The transaction is expected to close in the first quarter of 2026.</li></ul>Shares of RAPT Therapeutics (RAPT) surged 63% in pre-market trading on Tuesday after GSK Plc announced a definitive agreement to acquire the California-based clinical-stage biopharmaceutical company for around $2.2 billion.Under the agreement, GSK will acquire RAPT for $58.00 per share in cash, a 65.2% premium over Friday’s closing price of $35.1. GSK’s upfront investment is estimated at about $1.9 billion. The transaction is expected to close in the first quarter of 2026.If the level holds after the opening bell, RAPT shares will climb to their highest levels since May 2024.<h2 class="st-heading-2">What Is The Deal About?</h2>The agreement centers on Ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody currently in phase IIb development for the prevention of food allergy reactions. IgE remains the only approved systemic therapy proven to protect patients from severe allergic and inflammatory immune responses. The acquisition will add to GSK’s respiratory, immunology &amp; inflammation pipeline.The deal grants GSK global rights to Ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong. GSK will also assume responsibility for success-based milestone and royalty payments owed to RAPT’s partner, Shanghai Jeyou Pharmaceutical.Existing anti-IgE therapies typically require injections every two to four weeks, but Ozureprubart has the potential to reduce dosing frequency to once every 12 weeks. It may also expand treatment access to roughly 25% of patients who are currently ineligible for existing therapies.The Food and Drug Administration (FDA) had cleared the company’s investigational new drug (IND) application to advance Ozureprubart into a Phase IIb food allergy trial in September, and in October, RAPT launched the prestIgE study, a randomized, double-blind, placebo-controlled trial. Phase IIb data from the prestIgE trial are expected in 2027, with phase III studies planned in both adult and pediatric populations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/RAPT">RAPT</a> turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘high’ message volumes, while sentiment for GSK’s U.S.-listed shares remained in the ‘neutral’ zone.<img src="https://news.stocktwits-cdn.com/RAPT_jpg_5e9736f28c.webp" alt="RAPT.jpg">Over the past year, RAPT stock has gained more than 250%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvda-stock-down-in-premarket-today/cmUuhayR4aB">Why Is NVDA Stock Down 3% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did RAPT Stock Surge 63% In Pre-Market Today?

GSK will acquire RAPT for $58.00 per share in cash, a 65.2% premium over Friday’s closing price of $35.1.

RAPT Stock Soars On GSK Takeover Deal Valuing Company At $2.2 Billion

Equity

GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough

GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.read more...

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

RAPT
RAPT Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RAPT News

RAPTRAPT Therapeutics Inc